Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying ASP2138, a drug that targets the protein Claudin 18.2 CLDN18.2 found on digestive system cells and some tumors, including stomach cancer, gastroesophageal junction GEJ cancer, and pancreatic cancer. This study aims to understand how ASP2138 works in the body and to find safe and suitable doses when given alone or combined with standard treatments. The goal is to check safety, tolerance, and dosing for ASP2138 in adults with locally advanced unresectable or metastatic cancers that express CLDN18.2. The study includes two main phases. In Phase 1, participants receive escalating doses of ASP2138 either by intravenous infusion or subcutaneous injection, given alone or with one of three standard treatments pembrolizumab with mFOLFOX6, ramucirumab with paclitaxel, or mFOLFIRINOX, depending on their cancer type. Phase 1b uses doses determined in Phase 1 to treat participants with these regimens. The study also includes an end-of-treatment visit about 7 days after the last dose or if treatment stops early. Participants undergo regular safety monitoring including assessments for side effects, vital signs, laboratory tests, electrocardiograms, and physical exams up to 27 months. Researchers also measure how the drug is processed in the body and evaluate tumor response using imaging and biomarkers. Participants must meet specific health and tumor criteria and are followed closely throughout the treatment and safety periods to evaluate ASP2138s effects and tolerability.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new drug called daraxonrasib compared to the chemotherapy drug docetaxel in patients with non-small cell lung cancer NSCLC who have specific RAS gene mutations and have already received treatment. This global, randomized, open-label Phase 3 study aims to find out if daraxonrasib can improve how long patients live without their cancer worsening or overall survival compared to standard chemotherapy. Participants are randomly assigned to one of two groups one group receives daraxonrasib as oral tablets, and the other group receives docetaxel through intravenous infusion. The study follows patients over several years to compare the outcomes of these treatments. Patients receive treatment according to their assigned group and are monitored regularly throughout the study period. During the study, participants will have assessments including scans to measure tumor size, tests to check organ function, and questionnaires about quality of life. Researchers will evaluate progression-free survival and overall survival as main outcomes, along with the safety and tolerability of the treatments. The study lasts up to approximately four years, with ongoing monitoring of patients health and treatment responses.